Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha 2b topical - Helix BioPharma

Drug Profile

Interferon alpha 2b topical - Helix BioPharma

Alternative Names: AP-001; Interferon-alpha-2b - Helix BioPharma

Latest Information Update: 29 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helix BioPharma
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cervical dysplasia; Genital warts

Most Recent Events

  • 23 Dec 2016 Xisle and Altum Pharmaceuticals agree to co-develop interferon alpha 2b for Cervical dysplasia
  • 23 Dec 2016 Xisle Pharma Ventures Trust in-licenses Biphasix™ technology platform, including Interferon alpha 2b topical for the treatment of Cervical dysplasia (HPV-induced), from Helix BioPharma
  • 17 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top